Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan1, Mary O'Reilly1, Ray McDermott1
1Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
Abstract:
Targeting the RAS pathway remains the holy grail of precision oncology. In the case of pancreatic ductal adenocarcinomas (PDAC), 90-92% harbor mutations in the oncogene KRAS, triggering canonical MAPK signaling. The smooth structure of the altered KRAS protein without a binding pocket and its affinity for GTP have, in the past, hampered drug development. The emergence of KRASG12C covalent inhibitors has provided renewed enthusiasm for targeting KRAS. The numerous pathways implicated in RAS activation do, however, lead to the development of early resistance. In addition, the dense stromal niche and immunosuppressive microenvironment dictated by oncogenic KRAS can influence treatment responses, highlighting the need for a combination-based approach. Given that mutations in KRAS occur early in PDAC tumorigenesis, an understanding of its pleiotropic effects is key to progress in this disease. Herein, we review current perspectives on targeting KRAS with a focus on PDAC.
Insights
Targeting KRAS mutations in pancreatic cancer is crucial. New KRAS inhibitors offer hope, but combination therapies are needed due to resistance and the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is driven by KRAS mutations in 90-92% of cases, activating MAPK signaling.
- The KRAS protein's structure and GTP affinity have historically challenged drug development.
- KRAS mutations are early events in PDAC tumorigenesis, influencing tumor progression.
Purpose of the Study:
- To review current strategies for targeting KRAS in PDAC.
- To discuss challenges and opportunities in developing KRAS-targeted therapies.
- To highlight the need for combination approaches considering resistance mechanisms and the tumor microenvironment.
Main Methods:
- Review of current literature on KRAS targeting in oncology.
- Analysis of resistance mechanisms and the role of the tumor microenvironment.
- Focus on KRAS G12C inhibitors and their implications for PDAC.
Main Results:
- Emergence of KRAS G12C covalent inhibitors has renewed interest in targeting KRAS.
- RAS pathway activation leads to early resistance.
- The PDAC stromal niche and immunosuppressive microenvironment impact treatment response.
Conclusions:
- Targeting KRAS is essential for precision oncology in PDAC.
- Combination therapies are necessary to overcome resistance and the tumor microenvironment.
- Understanding KRAS's pleiotropic effects is key for advancing PDAC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38The Ras Gene
Ras is a...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...